Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
Status: | Completed |
---|---|
Conditions: | Anemia, Hematology |
Therapuetic Areas: | Hematology |
Healthy: | No |
Age Range: | 12 - 65 |
Updated: | 11/17/2018 |
Start Date: | December 20, 2013 |
End Date: | September 23, 2016 |
A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures
The purpose of the study is to evaluate the efficacy and safety of BAX 855 in severe
hemophilia A previously treated (PTP) males, 12 to 65 years of age who are undergoing
elective surgical or other invasive procedures.
hemophilia A previously treated (PTP) males, 12 to 65 years of age who are undergoing
elective surgical or other invasive procedures.
Inclusion Criteria:
- Participant requires an elective major or minor surgical, dental or other invasive
procedure (e.g. biopsy, endoscopy).
- Participant and/or legal representative has/have provided signed informed consent.
- Participant has severe hemophilia A (Factor VIII (FVIII) level <1%) as confirmed by
the central lab at screening or a documented FVIII activity level <1%.
- Participant was previously treated with FVIII concentrates with ≥150 documented
exposure days (EDs).
- Participant is currently receiving prophylaxis or on-demand therapy with FVIII
concentrate.
- Participant has a Karnofsky performance score of ≥60 at screening.
- Participant is human immunodeficiency virus negative (HIV-); or HIV+ with stable
disease and CD4+ count ≥200 cells/mm^3, as confirmed by central laboratory at
screening.
- Participant is Hepatitis C virus negative (HCV-) by antibody or PCR testing (if
positive, antibody titer will be confirmed by PCR), as confirmed by central laboratory
at screening; or HCV+ with chronic stable hepatitis as assessed by the investigator.
- Participant is willing and able to comply with the requirements of the study protocol.
Exclusion Criteria:
- Participant has detectable FVIII inhibitory antibodies (≥0.4 Bethesda Unit (BU) using
the Nijmegen modification of the Bethesda assay) at screening as determined by the
central laboratory or at any timepoint prior to screening (≥0.4 BU using the Nijmegen
modification of the Bethesda assay or ≥0.6 BU using the Bethesda assay).
- History of ongoing or recent thrombotic disease, fibrinolysis or disseminated
intravascular coagulation (DIC).
- Participant has a platelet count <100 x 10^9/L, as confirmed by central laboratory at
screening.
- Participant has severe renal impairment (serum creatinine > 2.0 mg/dL), as confirmed
by central laboratory at screening.
- Participant has severe chronic hepatic dysfunction (eg ≥5 X upper limit of normal
alanine aminotransferase (ALT), as confirmed by the central laboratory at screening,
or a documented International Normalized Ratio (INR) > 1.5).
- Participant has a known hypersensitivity towards mouse or hamster proteins,
polysorbate 80 or to PEG.
- Participant is currently using or has recently (< 30 days) used pegylated drugs (other
than BAX 855) prior to study participation or is scheduled to use such drugs during
trial participation.
- Participant is currently participating in another clinical drug (other than BAX 855)
or device study or use of another investigational product or device within 30 days
prior to study entry.
- Participant has a diagnosis of an inherited or acquired hemostatic defect other than
hemophilia A.
- Participant is currently receiving, or scheduled to receive during the course of the
study, an immunomodulating drug (eg, systemic corticosteroid agent at a dose
equivalent to hydrocortisone >10 mg/day, or alpha interferon) other than
anti-retroviral chemotherapy.
- Participant has a clinically significant medical, psychiatric, or cognitive illness,
or recreational drug/alcohol use that, in the opinion of the investigator, would
affect participant safety or compliance.
We found this trial at
9
sites
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
Cincinnati, Ohio 45229
1-513-636-4200
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
Click here to add this to my saved trials
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
Hershey, Pennsylvania 17033
(717) 531-6955
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Louisville The University of Louisville is a state supported research university located in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials